OncoMatch/Clinical Trials/NCT07833566
Biopsy-site-marker in Breast Cancer
Official title: Inflammation and Biopsy-site-marker in Breast Cancer (MOSAIC)
Is NCT07833566 recruiting? Yes, currently enrolling (Oct 2026). Studying Biopsy-Site Marker Placement. for breast cancer.
Treatment: Biopsy-Site Marker Placement. — The purpose of this study is to explore pro-metastatic changes in breast cancer (BC) associated with the stiffness of biopsy site markers. This study aims to determine whether the stiffness of a biopsy site marker promotes inflammatory changes in breast cancer and to evaluate whether there is a relationship between biopsy site marker stiffness and inflammation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Demographics
Prior therapy
Cannot have received: neoadjuvant therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OU Health Stephenson Cancer Center · Oklahoma City, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07833566 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant therapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages